RHX 889
Alternative Names: RHX-889Latest Information Update: 28 Jan 2024
Price :
$50 *
At a glance
- Originator Rheos Medicines
- Developer Rheos Medicines; Roche
- Class Antirheumatics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for research development in Multiple-sclerosis in USA
- 28 Jan 2024 No recent reports of development identified for research development in Rheumatoid-arthritis in USA
- 10 Mar 2021 RHX 889 is available for licensing as of 10 Mar 2021. https://rheosrx.com/contact/